|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Dr. Sanjay S. Shukla M.D., M.S.||President, CEO & Director||795.48k||N/D||1972|
|Ms. Jill M. Broadfoot||Chief Financial Officer||556.62k||N/D||1962|
|Ms. Nancy E. Denyes Krueger||General Counsel & Corporate Secretary||532.13k||N/D||1968|
|Xiang-Lei Yang Ph.D.||Founder||N/D||N/D||N/D|
|Ms. Ashlee Dunston||Director of Investor Relations & Corporate Communications||N/D||N/D||N/D|
|Mr. Peter Villiger||Vice President of Corporate Development||N/D||N/D||N/D|
|Ms. Danielle Campbell||VP of Human Resource||N/D||N/D||N/D|
|Dr. Leslie Nangle Ph.D.||Vice President of Research||N/D||N/D||N/D|
|Dr. Ying J. Buechler Ph.D.||Executive Director of Biologics Development & Manufacturing||N/D||N/D||N/D|
|Dr. David J. King||Scientific Consultant||327.31k||N/D||1959|
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de aTyr Pharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.